Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

658 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Asakura M, Kim J, Asanuma H, Hamasaki T, Tsukahara K, Higashino Y, Ishikawa T, Nakama Y, Koba S, Maruyama Y, Tsujimoto M, Himeno H, Ohkusa T, Fujino S, Shimizu M, Endo T, Yoda S, Muroya T, Murohara T, Ohte N, Suzuki H, Kohno T, Fukui K, Shiono T, Takase H, Uzui H, Nagai Y, Hashimoto Y, Ikeda S, Mizuno S, Tamita K, Fujita M, Satake K, Kinoshita Y, Nunohiro T, Sakagami S, Higaki J, Morii I, Sawada R, Hiasa Y, Shigemasa T, Nakahama M, Sata M, Doi O, Ueda T, Yamada T, Yamanouchi T, Yamaguchi H, Morita Y, Hayashi H, Kitakaze M; ABC investigators. Asakura M, et al. Among authors: hamasaki t. Cardiovasc Drugs Ther. 2017 Aug;31(4):401-411. doi: 10.1007/s10557-017-6740-3. Cardiovasc Drugs Ther. 2017. PMID: 28779371 Clinical Trial.
Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone: Reports of a Randomised Trial From The Japan Working Group for the Assessment Whether Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study).
Asakura M, Kim J, Asanuma H, Nakama Y, Tsukahara K, Higashino Y, Ishikawa T, Koba S, Tsujimoto M, Himeno H, Maruyama Y, Ookusa T, Yoda S, Suzuki H, Okubo S, Shimizu M, Hashimoto Y, Satake K, Fujino S, Uzui H, Nagai Y, Kohno T, Mizuno S, Nakahama M, Kanaya H, Murohara T, Fukui K, Takase H, Ohte N, Shiono T, Fukunami M, Endo T, Sawada R, Fujii K, Takeuchi M, Ikeda S, Mizuno K, Uematsu M, Matsubara T, Yano S, Takahashi J, Ueda K, Kinoshita Y, Tamita K, Hayashi H, Hamasaki T, Kitakaze M; PPAR investigators. Asakura M, et al. Among authors: hamasaki t. EClinicalMedicine. 2018 Oct 22;4-5:10-24. doi: 10.1016/j.eclinm.2018.09.006. eCollection 2018 Oct-Nov. EClinicalMedicine. 2018. PMID: 31193597 Free PMC article.
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Yoshihara F, Imazu M, Hamasaki T, Anzai T, Yasuda S, Ito S, Yamamoto H, Hashimura K, Yasumura Y, Mori K, Watanabe M, Asakura M, Kitakaze M; DAPPER investigators and study coordinators. Yoshihara F, et al. Among authors: hamasaki t. Cardiovasc Drugs Ther. 2018 Apr;32(2):183-190. doi: 10.1007/s10557-018-6782-1. Cardiovasc Drugs Ther. 2018. PMID: 29589153
Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial.
Takahama H, Asakura M, Abe Y, Ajioka M, Aonuma K, Anzai T, Hayashi T, Hiramitsu S, Kawai H, Kioka H, Kimura K, Lim YJ, Matsuoka K, Motoki H, Nagata Y, Nakamura S, Ohte N, Ozaki Y, Sasaoka T, Tamaki S, Hamasaki T, Kitakaze M; J-TASTE investigators. Takahama H, et al. Among authors: hamasaki t. Cardiovasc Drugs Ther. 2018 Aug;32(4):381-388. doi: 10.1007/s10557-018-6799-5. Cardiovasc Drugs Ther. 2018. PMID: 29974299
Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M; TOPLEVEL investigators and study coordinators. Imazu M, et al. Among authors: hamasaki t. Cardiovasc Drugs Ther. 2019 Jun;33(3):363-370. doi: 10.1007/s10557-019-06871-3. Cardiovasc Drugs Ther. 2019. PMID: 30850916
Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.
Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S; J-WIND investigators. Kitakaze M, et al. Among authors: hamasaki t. Lancet. 2007 Oct 27;370(9597):1483-93. doi: 10.1016/S0140-6736(07)61634-1. Lancet. 2007. PMID: 17964349 Clinical Trial.
Does the pathophysiology of heart failure prime the incidence of cancer?
Sakamoto M, Hasegawa T, Asakura M, Kanzaki H, Takahama H, Amaki M, Mochizuki N, Anzai T, Hamasaki T, Kitakaze M. Sakamoto M, et al. Among authors: hamasaki t. Hypertens Res. 2017 Sep;40(9):831-836. doi: 10.1038/hr.2017.45. Epub 2017 Apr 6. Hypertens Res. 2017. PMID: 28381869
Association of lifestyle-related factors with circadian onset patterns of acute myocardial infarction: a prospective observational study in Japan.
Edahiro R, Sakata Y, Nakatani D, Suna S, Usami M, Matsumoto S, Hara M, Kitamura T, Sato H, Yamashita S, Nanto S, Hikoso S, Sakata Y, Hori M, Hamasaki T, Komuro I; OACIS Investigators. Edahiro R, et al. Among authors: hamasaki t. BMJ Open. 2014 Jun 6;4(6):e005067. doi: 10.1136/bmjopen-2014-005067. BMJ Open. 2014. PMID: 24907246 Free PMC article.
658 results